Baili Tianheng announced that Yizekang®, the world's first EGFR × HER3 dual antibody ADC independently developed by the company, was included in the list of priority review varieties by the Drug Evaluation Center of the State Drug Administration. The proposed indication is locally advanced or metastatic non-squamous non-squamous non-small cell lung cancer with EGFR-sensitive mutations that failed to be treated with EGFR-TKI. The reason was included in the breakthrough treatment drug procedure for priority review according to relevant regulations. Up to now, 3 indications of Yizekang® have been included in the CDE list of priority review varieties, and 9 indications have been included in the CDE list of breakthrough treatment varieties.

Baili Tianheng announced that Yizekang®, the world's first EGFR × HER3 dual antibody ADC independently developed by the company, was included in the list of priority review varieties by the Drug Evaluation Center of the State Drug Administration. The proposed indication is locally advanced or metastatic non-squamous non-squamous non-small cell lung cancer with EGFR-sensitive mutations that failed to be treated with EGFR-TKI. The reason was included in the breakthrough treatment drug procedure for priority review according to relevant regulations. Up to now, 3 indications of Yizekang® have been included in the CDE list of priority review varieties, and 9 indications have been included in the CDE list of breakthrough treatment varieties.